Genitourinary Cancers

Kyle A. Richards, MD, assistant professor, University of Wisconsin, discusses the association between urinary tract infections (UTI) and worse bladder cancer outcomes in the Medicare population.

Alexander Kutikov, MD, FACS, attending surgeon, urologic oncology, associate professor, urologic oncology, Fox Chase Cancer Center, discusses the understanding of tumor pathology in renal cell carcinoma.

Thomas E. Hutson, DO, PharmD, medical oncologist, Director of Genito-Urinary at Texas Oncology–Baylor Charles A. Sammons Cancer Center, discusses drug sequencing for the treatment of renal cell carcinoma.

Laurence Albiges, MD, visiting scientist, Dana-Farber Cancer Institute, discusses how oncologists can treat patients with metastatic renal cell carcinoma (mRCC) based off of findings from a study that looked at the impact of body mass index (BMI) on outcomes of these patients.

Management of elevated PSAs, or the next testing equivalent, and prostate cancer should default to the urology world, just like always.

Arjun V. Balar, MD, oncologist, NYU Langone Medical Center, discusses the results of the phase III ASSURE trial, which compared sorafenib and sunitinib in patients with locally advanced renal cell carcinoma (RCC).

Older, single white males with advanced bladder cancer have the highest suicide risk among those with other cancers of the male genitals and urinary system, researchers report.